A Single Dose of ACE-011 Is Associated with Increases in Bone Formation and Decreases in Bone Resorption Markers in Healthy, Postmenopausal Women

Trial Profile

A Single Dose of ACE-011 Is Associated with Increases in Bone Formation and Decreases in Bone Resorption Markers in Healthy, Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2009

At a glance

  • Drugs Sotatercept; Sotatercept
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 01 Apr 2009 Results have been reported in the British Journal of Clinical Pharmacology.
    • 19 Dec 2008 Results published in the Journal of Bone and Mineral Research.
    • 19 Sep 2007 Postive results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top